Late-Life Functional Restoration and Frailty Reversal with SS-31

This study specifically analyzed whether treating mice at advanced ages could reverse established markers of physical decline.

• Professional Title: "Mitigation of Sarcopenic Pathways and Frailty Accumulation via Targeted Cardiolipin-Stabilizing Peptide Therapeutics"

• Journal Context: bioRxiv / PubMed | Principal Investigators: Mitchell, W., Pharaoh, G., Tyshkovskiy, A., Marcinek, D. J., Gladyshev, V. N., et al. (Harvard Medical School / University of Washington)

• Methodology: Advanced-age murine models (24 months old, roughly equivalent to a 70-year-old human) were administered continuous systemically delivered Elamipretide (SS-31) via subcutaneous osmotic mini-pumps over a fixed 8-week cycle (Mitchell et al., 2024). Researchers tracked changes in the clinical Frailty Index, cardiac strain, and skeletal muscle force output (Mitchell et al., 2024).

• Key Findings: * Frailty Reversal: Despite aging an additional two months during the observation window, the active treatment cohort experienced a distinct decrease in their overall Frailty Index, indicating an improvement in systemic physiological robustness (Mitchell et al., 2024).

  • Transcriptomic Pro-Longevity Shifts: While the peptide did not alter the core epigenetic or transcriptomic "clock age" of the tissues, global pathway analysis revealed significant pro-longevity shifts in gene expression (Mitchell et al., 2024). This included the structural upregulation of genes controlling mitochondrial translation, fatty acid metabolism, and oxidative phosphorylation, alongside a concurrent downregulation of systemic inflammatory cascades ("inflammaging") (Mitchell et al., 2024).